Abstract

背景与目的已有的研究表明, 端粒酶的异常活化与肺癌的发生、发展及转归密切相关, 端粒酶是目前已知广谱的肿瘤分子标记物, 是诊断和治疗肺癌的重要分子标志物之一。本研究旨在探讨诱导痰、胸水和纤维支气管镜活检组织中端粒酶活性的联合检测对肺癌的诊断价值。方法对80例肺癌伴胸水患者和50例肺部良性病变伴胸水患者, 应用TRAP-PCR-ELISA方法分别检测其诱导痰、胸水和纤维支气管镜活检组织中端粒酶的活性。结果肺癌伴胸水患者诱导痰、胸水和纤维支气管镜活组织中端粒酶的活性均明显高于肺部良性病变伴胸水患者(P < 0.001), 不同病理类型的肺癌患者间三种标本的端粒酶活性差异无统计学意义(P > 0.05)。诱导痰、胸水和纤维支气管镜活组织中端粒酶活性的检测对肺癌的诊断敏感性分别为62.5%(50/80)、46.3%(37/80)和60.0%(48/80);特异性分别为72.0%(36/50)、66.0%(33/50)和70.0%(35/50);准确性分别为66.2%(86/130)、53.8%(70/130)和63.8%(83/130);三项联合检测的敏感性、特异性和准确性分别为85.0%(68/80)、78.0%(39/50)和82.3%(107/130), 其中敏感性与单独诱导痰、胸水和纤维支气管镜活组织的敏感性差异有统计学意义(P < 0.01)。结论诱导痰、胸水和纤维支气管镜活组织端粒酶活性的联合检测具有更高的敏感性, 可以提高肺癌的诊断率。

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.